HRT Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

HRT Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$139K	Buy	+45,500	New	+$176K	﹤0.01%	3284

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRT Financial's RXRX Position: Q1 2026 in Review

HRT Financial sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 256,571 shares — an estimated $991K sold.

HRT Financial first reported a position in RXRX in Q1 2022 and held it in 5 quarters. The position peaked at $2.75M in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

HRT Financial reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 256,571 Recursion Pharmaceuticals shares in Q1 2026, an estimated $991K.
HRT Financial first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 5 quarters.
HRT Financial's Recursion Pharmaceuticals position peaked at $2.75M in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.